Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $964.33 | 17 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Madrigal Pharmaceuticals | $382.91 | 3 | $0 (2024) |
| Veloxis Pharmaceuticals, Inc. | $106.77 | 1 | $0 (2023) |
| ORPHALAN INC | $92.19 | 1 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $88.69 | 1 | $0 (2021) |
| AbbVie, Inc. | $78.50 | 5 | $0 (2019) |
| Intercept Pharmaceuticals, Inc. | $76.77 | 1 | $0 (2018) |
| CooperSurgical, Inc. | $64.13 | 1 | $0 (2018) |
| FUJIFILM Healthcare Americas Corporation | $27.92 | 1 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $17.21 | 1 | $0 (2019) |
| Bayer HealthCare Pharmaceuticals Inc. | $16.26 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $503.02 | 5 | Madrigal Pharmaceuticals ($382.91) |
| 2023 | $106.77 | 1 | Veloxis Pharmaceuticals, Inc. ($106.77) |
| 2021 | $88.69 | 1 | AstraZeneca Pharmaceuticals LP ($88.69) |
| 2020 | $12.98 | 1 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($12.98) |
| 2019 | $79.03 | 5 | AbbVie, Inc. ($61.82) |
| 2018 | $140.90 | 2 | Intercept Pharmaceuticals, Inc. ($76.77) |
| 2017 | $32.94 | 2 | AbbVie, Inc. ($16.68) |
All Payment Transactions
17 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/19/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $132.68 | General |
| Category: LIVER DISEASE | ||||||
| 11/18/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $134.83 | General |
| Category: LIVER DISEASE | ||||||
| 11/17/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $115.40 | General |
| Category: LIVER DISEASE | ||||||
| 09/26/2024 | FUJIFILM Healthcare Americas Corporation | UTASWAKO AFP-L3 (Device) | Food and Beverage | In-kind items and services | $27.92 | General |
| Category: Medical Device | ||||||
| 06/26/2024 | ORPHALAN INC | CUVRIOR (Drug) | Food and Beverage | In-kind items and services | $92.19 | General |
| Category: Hepatology | ||||||
| 01/26/2023 | Veloxis Pharmaceuticals, Inc. | ENVARSUS (Drug) | Food and Beverage | In-kind items and services | $106.77 | General |
| Category: TRANSPLANTATION | ||||||
| 12/09/2021 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $88.69 | General |
| 01/24/2020 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $12.98 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/04/2019 | Alexion Pharmaceuticals, Inc. | Kanuma (Drug) | Food and Beverage | In-kind items and services | $17.21 | General |
| Category: Immunology | ||||||
| 10/16/2019 | AbbVie, Inc. | Mavyret (Drug) | Food and Beverage | In-kind items and services | $17.72 | General |
| Category: Virology | ||||||
| 09/04/2019 | AbbVie, Inc. | Mavyret (Drug) | Food and Beverage | In-kind items and services | $13.77 | General |
| Category: Virology | ||||||
| 08/14/2019 | AbbVie, Inc. | Mavyret (Drug) | Food and Beverage | In-kind items and services | $13.48 | General |
| Category: Virology | ||||||
| 07/03/2019 | AbbVie, Inc. | Mavyret (Drug) | Food and Beverage | In-kind items and services | $16.85 | General |
| Category: Virology | ||||||
| 11/29/2018 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $76.77 | General |
| Category: HEPATOLOGY GASTROENTEROLOGY | ||||||
| 11/20/2018 | CooperSurgical, Inc. | Endosee (Device) | Food and Beverage | In-kind items and services | $64.13 | General |
| Category: Obstetrics/Gynecology (Women's Health) | ||||||
| 11/08/2017 | AbbVie, Inc. | Mavyret (Drug) | Food and Beverage | In-kind items and services | $16.68 | General |
| Category: Virology | ||||||
| 10/10/2017 | Bayer HealthCare Pharmaceuticals Inc. | Stivarga (Drug), Nexavar | Food and Beverage | In-kind items and services | $16.26 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 166 | 204 | $54,488 | $16,779 |
| 2022 | 7 | 200 | 245 | $65,001 | $20,704 |
| 2021 | 7 | 220 | 281 | $73,826 | $24,822 |
| 2020 | 4 | 121 | 135 | $39,308 | $12,227 |
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 39 | 41 | $18,368 | $5,144 | 28.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 35 | 46 | $11,170 | $3,267 | 29.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 19 | 36 | $8,316 | $3,232 | 38.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 17 | 22 | $6,974 | $2,284 | 32.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 18 | 20 | $5,060 | $1,583 | 31.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 24 | 25 | $4,096 | $1,171 | 28.6% |
| 91200 | Measurement of liver stiffness | Facility | 2023 | 14 | 14 | $504.00 | $97.92 | 19.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 75 | 95 | $22,445 | $6,750 | 30.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 26 | 39 | $12,363 | $4,381 | 35.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 23 | 23 | $10,304 | $3,617 | 35.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 21 | 21 | $7,581 | $2,049 | 27.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 16 | 25 | $5,775 | $2,031 | 35.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 11 | 11 | $3,185 | $953.46 | 29.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 16 | 18 | $2,880 | $839.24 | 29.1% |
| 91200 | Measurement of liver stiffness | Facility | 2022 | 12 | 13 | $468.00 | $84.20 | 18.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 91 | 118 | $27,970 | $9,064 | 32.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 31 | 34 | $15,232 | $5,477 | 36.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 30 | 39 | $12,363 | $4,459 | 36.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 17 | 31 | $7,161 | $2,574 | 35.9% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 18 | 18 | $6,648 | $1,783 | 26.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 17 | 24 | $3,840 | $1,315 | 34.2% |
| 91200 | Measuring the stiffness in the liver via elastography | Facility | 2021 | 16 | 17 | $612.00 | $149.78 | 24.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 66 | 67 | $16,225 | $4,186 | 25.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 25 | 25 | $11,200 | $4,057 | 36.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 15 | 28 | $6,468 | $2,384 | 36.9% |
About Dr. Steven Young, M.D
Dr. Steven Young, M.D is a Surgery healthcare provider based in New Orleans, Louisiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/16/2014. The National Provider Identifier (NPI) number assigned to this provider is 1629498787.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Steven Young, M.D has received a total of $964.33 in payments from pharmaceutical and medical device companies, with $503.02 received in 2024. These payments were reported across 17 transactions from 11 companies. The most common payment nature is "Food and Beverage" ($964.33).
As a Medicare-enrolled provider, Young has provided services to 707 Medicare beneficiaries, totaling 865 services with total Medicare billing of $74,532. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.
Practice Information
- Specialty Surgery
- Other Specialties Student in an Organized Health Care Education/Training Program, Gastroenterology
- Location New Orleans, LA
- Active Since 04/16/2014
- Last Updated 09/01/2020
- Taxonomy Code 208600000X
- Entity Type Individual
- NPI Number 1629498787
Products in Payments
- RESMETIROM (Drug) $382.91
- ENVARSUS (Drug) $106.77
- CUVRIOR (Drug) $92.19
- Mavyret (Drug) $78.50
- OCALIVA (Drug) $76.77
- Endosee (Device) $64.13
- UTASWAKO AFP-L3 (Device) $27.92
- Kanuma (Drug) $17.21
- Stivarga (Drug) $16.26
- XIFAXAN (Drug) $12.98
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Surgery Doctors in New Orleans
Dr. Carlos Galvani, M.d, M.D
Surgery — Payments: $387,443
Dr. Joseph Buell, Md, MD
Surgery — Payments: $317,599
Aditya Bansal, Md, MD
Surgery — Payments: $194,462
Dr. Michael Cook, M. D, M. D
Surgery — Payments: $63,905
Jennifer Paruch, M.d, M.D
Surgery — Payments: $45,054
Dr. Ian Hodgdon, Md, MD
Surgery — Payments: $39,035